Plus Therapeutics Inc (PSTV) recently have taken one step ahead with the beta value of 0.66

Plus Therapeutics Inc (NASDAQ: PSTV) started the day on Thursday, with a price increase of 4.91% at $0.29, before settling in for the price of $0.27 at the close. Taking a more long-term approach, PSTV posted a 52-week range of $0.24-$2.67.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 383.24%. Meanwhile, its Annual Earning per share during the time was 46.51%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 57.69%. This publicly-traded company’s shares outstanding now amounts to $17.00 million, simultaneously with a float of $15.49 million. The organization now has a market capitalization sitting at $4.87 million. At the time of writing, stock’s 50-day Moving Average stood at $0.7346, while the 200-day Moving Average is $1.1339.

Plus Therapeutics Inc (PSTV) Ownership Facts and Figures

Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Plus Therapeutics Inc’s current insider ownership accounts for 8.87%, in contrast to 9.41% institutional ownership. Preceding that transaction, on Sep 13 ’24, Company’s Director bought 4,000 for 1.50, making the whole transaction’s value amount to 5,996. This particular insider is now the holder of 15,188 in total.

Plus Therapeutics Inc (PSTV) Earnings and Revenue Records

Plus Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 57.69% and is forecasted to reach -0.76 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 49.89% through the next 5 years, which can be compared against the 46.51% growth it accomplished over the previous five years trading on the market.

Plus Therapeutics Inc (NASDAQ: PSTV) Trading Performance Indicators

Let’s observe the current performance indicators for Plus Therapeutics Inc (PSTV). It’s Quick Ratio in the last reported quarter now stands at 0.31. The Stock has managed to achieve an average true range (ATR) of 0.10. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 0.84.

In the same vein, PSTV’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.06, a figure that is expected to reach -0.25 in the next quarter, and analysts are predicting that it will be -0.76 at the market close of one year from today.

Technical Analysis of Plus Therapeutics Inc (PSTV)

If we take a close look at the recent performances of Plus Therapeutics Inc (NASDAQ: PSTV), its last 5-days Average volume was 2.44 million that shows plunge from its year to date volume of 10.95 million. During the previous 9 days, stock’s Stochastic %D was recorded 7.56% While, its Average True Range was 0.0752.

Raw Stochastic average of Plus Therapeutics Inc (PSTV) in the period of the previous 100 days is set at 2.24%, which indicates a major fall in contrast to 5.43% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 163.92% that was lower than 349.50% volatility it exhibited in the past 100-days period.

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.